Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06067399 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Dec 30, 2025 → Dec 30, 2027
See other at-risk trials from New Valley University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 30, 2025 to Dec 30, 2027
    • Start date changed from estimate of Dec 1, 2025 to May 1, 2026
    • Study completion pushed from Jun 30, 2026 to Jun 30, 2028
    v6
  2. Start date: Dec 1, 2024 to Dec 1, 2025v5
  3. Primary completion date: Dec 30, 2024 to Dec 30, 2025
    • Start date: Apr 1, 2024 to Dec 1, 2024
    • Study completion date: Jun 30, 2025 to Jun 30, 2026
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 25, 2023 to Apr 1, 2024
    • Study sites: 0 to 1
    v3
  5. Eligibility criteria expanded, about 39 words
    • Study arms: 3 to 2
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
New Valley University
16 trials monitored
See 2 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.
Trial Details
NCT Number NCT06067399
Lead Sponsor New Valley University
Conditions
(from sponsor)		 Type 2 Diabetes
Related terms Diabetes Mellitus, Type 2
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov